33-R-015	2_FP2	Pr_E900
33-R-015	52_FY2	f_E.pdf

Academ be Pageneok Beaked and Acid 1984. In genery may of emailed a grant and analysis of emails of a second a second of a sec			001(0102_1121_E.pdi		
Intergraph and register and method with the data method in method in method in method in method in the data method in moderate metantical in providing the approval for human use. Earlier studies method in method i	collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0579-0036. The time required to complete this information collection is estimated to average .5 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the				
Fiscal year: 2021 UNITED STATES DEPARTMENT OF AGRICULTURE ANIMAL AND PLANT HEALTH INSPECTION SERVICE Annual Report of Research Facility Column E Explanation Colspan="2">Colspan="2"			Interagency Report Control No. 0180-DOA-AN		
ANIMAL AND PLANT HEALTH INSPECTION SERVICE Annual Report of Research Facility Column E Explanation UNPE CORPUTE This information is required by law (7 U.S. C. 2143 and 9 C.F.R. § 2.30). Failure to report according to the regulations can result in an order to cease and desist. I. REGISTRATION NUMBER 33-R-0152 2. Research Facility Headquarters address North Chicago, IL 60064 3. Number of animals used in the study. 1 S. Explain the procedure producing pain and distress. Pre-dinical safety study. 6. Provide the scientific justification for not providing the appropriate anesthetics, analgesics, or tranquilizing drugs during procedures where the animal experienced accompanying pain or distress greater than momentary or slight. Animals were involved in pre-dinical drug safety studes mandated by 21 CFR 312.23(a)(8)(ii) and 21 CFR 314.50(d)(2) to determine safety of new pharmaceuticals prior to human trials and eventual approved resulted to dosing. Since intervention would interfere with interpretation of the results of this study, a humane endpoint of any clinical signs beyond those provoudy experienced was established to minimize undue pain and distress. Prevaled that mail to moderate neurologic signs, decreased appetite, and emesis were expected relative dosing. Since intervention would interfere with interpretation of the results of this study, a humane endpoint of any clinical signs beyond those providey experienced was established to minimize undue pain and distress. Prevaled that mail to moderate neurologics signs, decreased appetite, and emesis were expected relative dosing. Since intervention would interfere with interpretation of the results of this study, a humane endpoint of any clinical signs beyond those providey experienced neurological effects that warranted euthanasia on day 4 of dosing which led to lowering the dose for the high dose group for the remainder of the study.			Fiscal year: 2021		
 Pre-dinical safety study. 6. Provide the scientific justification for not providing the appropriate anesthetics, analgesics, or tranquilizing drugs during procedures where the animal experienced accompanying pain or distress greater than momentary or slight. Animals were involved in pre-clinical drug safety studies mandated by 21 CFR 312.23(a)(8)(ii) and 21 CFR 314.50(d)(2) to determine safety of new pharmaceuticals prior to human trials and eventual approval for human use. Earlier studies revealed that mild to moderate neurologic signs, decreased appetite, and emesis were expected relative to dosing. Since intervention would interfere with interpretation of the results of this study, a humane endpoint of any clinical signs beyond those previously experienced was established to minimize undue pain and distress. Increased monitoring was implemented to minimize adverse animal welfare effects. One dog experienced neurological effects that warranted euthanasia on day 4 of dosing which led to lowering the dose for the high dose group for the remainder of the study. 7. What, if any, Federal regulations require this procedure? Cite the agency, the Code of Federal Regulations (CFR) title number, and the specific section number (e.g., APHIS, 9 CFR) 	UNITED STATES DEPARTMENT OF AGRICULTURE ANIMAL AND PLANT HEALTH INSPECTION SERVICE Annual Report of Research Facility Column E Explanation (TYPE OR PRINT) This information is required by law (7 U.S. C. 2143 and 9 C.F.R. §2.36). Failure to report according to the regulations can result in an order to cease and desist. 1. REGISTRATION NUMBER 2. Research Facility Headquarters address 1 N. Waukegan Rd North Chicago, IL 60064 3. Number of animals used in the study. 4. Species (common name) of animals used in the study. Dog				
or tranquilizing drugs during procedures where the animal experienced accompanying pain or distress greater than momentary or slight. Animals were involved in pre-clinical drug safety studies mandated by 21 CFR 312.23(a)(8)(ii) and 21 CFR 314.50(d)(2) to determine safety of new pharmaceuticals prior to human trials and eventual approval for human use. Earlier studies revealed that mild to moderate neurologic signs, decreased appetite, and emesis were expected relative to dosing. Since intervention would interfere with interpretation of the results of this study, a humane endpoint of any clinical signs beyond those previously experienced was established to minimize undue pain and distress. Increased monitoring was implemented to minimize adverse animal welfare effects. One dog experienced neurological effects that warranted euthanasia on day 4 of dosing which led to lowering the dose for the high dose group for the remainder of the study. 7. What, if any, Federal regulations require this procedure? Cite the agency, the Code of Federal Regulations (CFR) title number, and the specific section number (e.g., APHIS, 9 CFR					
Federal Regulations (CFR) title number, and the specific section number (e.g., APHIS, 9 CFR	or tranquilizing drugs during procedures where the animal experienced accompanying pain or distress greater than momentary or slight. Animals were involved in pre-clinical drug safety studies mandated by 21 CFR 312.23(a)(8)(ii) and 21 CFR 314.50(d)(2) to determine safety of new pharmaceuticals prior to human trials and eventual approval for human use. Earlier studies revealed that mild to moderate neurologic signs, decreased appetite, and emesis were expected relative to dosing. Since intervention would interfere with interpretation of the results of this study, a humane endpoint of any clinical signs beyond those previously experienced was established to minimize undue pain and distress. Increased monitoring was implemented to minimize adverse animal welfare effects. One dog experienced neurological effects that warranted euthanasia on day 4 of dosing which led to lowering the dose for the high dose group for the remainder of the study.				
21 CFR 312.23(a)(8)(ii) and 21 CFR 314.50(d)(2)					
Agency CFR	Agency				
FDA 21 CFR 312.23(a)(8)(ii)					